Skip to content

Advancing Public Health

Six healthcare professionals attend to a patient suffering from COVID-19 in an operating room setting
ESG Policies & Positions

Access

We continuously seek to enhance access to our innovative medicines, vaccines and medical technologies in all countries—especially for underserved populations in resource-limited settings within the U.S. and around the world. Specifically, we are active in expanding access to many of our treatments targeted to halt the spread of different diseases such as HIV HIV Human immunodeficiency virus , TB TB Tuberculosis , Ebola and more—see section: Pandemics & Epidemics.

As a signatory to the Business for Social Responsibility (BSR) Guiding Principles on Access to Healthcare, we collaborate broadly across our industry to improve access for patients around the world.

Achievements from 2021 in advancing broader access considerations are as follows:

Leading the global access ranking: The 2021 Access to Medicine Index (ATMI) was released in January 2021, and we are proud to again rank as one of the top three companies advancing access to medicines in low- and middle-income countries around the world. The recognition of our leadership in this independent evaluation is the result of a longstanding, deliberate strategy aimed at solving some of the most difficult global health challenges and advancing equitable access to care for everyone, everywhere. The ATMI evaluates the world’s 20 largest phar

maceutical companies on their efforts to expand access to medicines. Each new Index raises the bar for the industry as the global health landscape changes and expectations for companies evolve.

Learn more

Our new Guide to Expanded Access (EA): EA is a pathway that seriously ill patients may consider in discussion with their treating physicians when they have exhausted available treatment options and are not eligible for clinical trials. With varied requirements and processes in every country, there is a burden on patients seeking information about this potential treatment pathway while also dealing with a serious or life-threatening diagnosis. To help bridge the information gap, our Patient Strategies & Solutions team, part of our Global Medical Organization, published a Guide to Expanded Access. The guide was co-created with patients and advocates to provide an overview of EA in 28 European countries and Canada and is available on Janssen.com.

Learn more

Johnson & Johnson products on the WHO List of Prequalified Medicinal Products

  • Darunavir (ethanolate), Tablet, Film-Coated 75mg
  • Darunavir (ethanolate), Tablet, Film-Coated 600mg
  • Etravirine, Tablet 25mg
  • Darunavir (ethanolate), Tablet, Film-Coated 150mg
  • Etravirine, Tablet, Film-Coated 100mg
  • Mebendazole, Tablets, Chewable 500mg

The WHO List of Prequalified Medicinal Products is designed to ensure that medicines supplied by procurement agencies meet acceptable standards of quality, safety and efficacy.

Johnson & Johnson products on the WHO List of Prequalified Vaccines

  • Mvabea (MVA-BN-Filo [recombinant]) Ebola vaccine
  • Zabdeno (Ad26.ZEBOV-GP [recombinant]) Ebola vaccine

Pricing transparency in the United States: In early 2022, we published our sixth annual Janssen U.S. Transparency Report, which highlights information related to our R&D investment, approach to pricing and patient support programs. Updates from this year’s report include:

  • The average net price decline of Janssen medicines in 2021 was (2.8%),* declining for the fifth year in a row.
  • Janssen paid $33.9 billion in rebates, discounts and fees in 2021, up 15.2% compared to 2020.*
  • Nearly 55% of the list price of our medicines went to commercial insurers and others in the healthcare system as rebates, discounts and fees.*
  • In 2021, Janssen CarePath provided access and affordability support to nearly 1.1 million patients.**

* Figures according to Janssen internal financial accounting.
** Data are an approximate number of patients supported by Janssen CarePath provided by the program administrator.

Patient Engagement

For our Positions on IP IP Intellectual Property and Universal Health Coverage, please visit ESG Policies & Positions.

Active collaboration with patients and caregivers helps guide our decision making throughout the product lifecycle and accelerate patient-inspired innovation. We aim to incorporate patients’ perspectives early in the development of medicines, medical devices and clinical trial protocols, and collaborate with patients to develop tailored solutions that empower them in managing their disease or condition.

Patient Engagement Research Councils (PERCs): Janssen Scientific Affairs maintains PERCs covering key disease areas. PERCs are a group of contracted individuals living with a condition of interest that our scientists can work with to quickly gather patient insights over time and thereby improve how we research, design studies and generate information. In 2021, we added the sixth PERC, covering multiple sclerosis (MS), with a goal of connecting with patients to better understand and integrate their needs and expectations into study development as they navigate their MS journey. The MS PERC consists of 12 racially and ethnically diverse MS patients from various parts of the U.S. We engaged this group to provide input to our new PONVO trial, a Phase 4, real-world observational study investigating fatigue in patients living with MS.

The PERC for the PONVO study enabled us to directly interact with patients before the trial started—to gain insights critical to making the clinical trial experience in PONVO more manageable and meaningful for participants. For example, we adjusted the frequency of data collection and the means of collection on the primary endpoint based on their feedback.
Allitia DiBernardo
Vice President, Global Medical Affairs, Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson

Other PERCs actively engaging patients in 2021:

  • atrial fibrillation;
  • bladder cancer;
  • peripheral arterial disease;
  • pulmonary arterial hypertension (PAH); and
  • venous thromboembolism.

Non-PERC patient engagement: Beyond our structured program for patient engagement, PERCs, we have experienced an increased demand for stand-alone market research projects that are driven by scientific objectives, where understanding patient experience is needed to inform internal research strategy. However, we aim to ensure all patient engagement is conducted ethically and consistently. To this end, we developed a set of Non-PERC Patient Engagement Guidelines by leveraging existing Market Research Operating Guidelines to drive standardization across therapeutic areas to integrate patient perspectives compliantly and efficiently into our work. In 2021, for example, the Non-PERC Patient Engagement Guidelines were used by our Medical Affairs team in research to understand drivers of patient satisfaction with TREMFYA (guselkumab) relative to other therapies for moderate to severe psoriasis. These insights informed internal decisions relating to the design of future longitudinal, prospective research.

Leveraging AI AI Artificial intelligence for improved adherence: Adherence is a significant factor in the efficacy of any treatment regimen. Faced with situations in which a high proportion of patients fail to fill their first prescription and even more fail to complete six months of therapy, colleagues at Johnson & Johnson concluded the development of an End-to-End Patient Engagement Program. The program is the first fully digital and AI-based patient journey management solution that provides real-time insights to activate patients and support prescribers. With this new tool, we expect to see adherence improvement and reduced delays in the patient journey.

Supporting clinical trial participants: MY TRIAL COMMUNITY is a web solution co-created with patients that helps clinical trial participants feel informed, engaged, secure and better connected. It offers features and benefits to support trial participants, caregivers and even researchers, including:

  • a dashboard explaining what participants can expect at each visit;
  • access to trial-related data during and after the trial to support ongoing health management;
  • individual clinical trial results; and
  • the potential for continuous clinical trial improvement and education through patient feedback.

Advancing patient advocacy and education: In 2021, we continued our HEALTHEVOICES patient advocate conferences, bringing together online health advocates to learn, share and connect. Our SUPER HEALTHEVOICES LIVE! event was held over three days with 42 sessions, featuring contributions from nearly 70 of the most influential online health advocates across a broad spectrum of health communities and therapeutic areas. We also held our second series of HEALTHEVOICES for HCPs HCPs Healthcare professional virtual events, to foster conversation among professionals in any area of healthcare practice and provide a platform for sharing insights and learning about new tools that better enable them to connect with patients online.

At Johnson & Johnson, we’re using the power of digital and data to engage patients and customers more effectively to improve inclusive access, enhance patient experience and deliver better outcomes. Digital technology helps us personalize treatments and accelerate improvements in the standard of care, which is why we are actively integrating new technologies across our healthcare innovation.
Jim Swanson
Executive Vice President, Enterprise Chief Information Officer, Johnson & Johnson
Previous Advancing Public Health Next R&D Innovation
Back to Top